Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 11;6(2):322–331. doi: 10.1002/iid3.220

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Percentage of total observations (at 8, 24, and 48 h and Day 7 combined) showing a two dose‐doubling increase in MCh PC₂₀ FEV1 compared with baseline. During the 7‐day post‐treatment observation period, N6022 produced a significant increase in the percentage of observations of two dose‐doubling increases in MCh PC₂₀ FEV1 compared with placebo. FEV₁, forced expiratory volume in 1 sec; MCh PC₂₀ FEV1, the provocative concentration of methacholine causing a 20% fall in FEV1.